{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Mozneb M"],"funding":["American Heart Association","NCATS NIH HHS","American Heart Association-American Stroke Association","Allen Institute","NHLBI NIH HHS","ALS Association","NINDS NIH HHS","National Institutes of Health","California Institute for Regenerative Medicine"],"pagination":["869-881"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12015978"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["24(4)"],"pubmed_abstract":["Cardiovascular toxicity causes adverse drug reactions and may lead to drug removal from the pharmaceutical market. Cancer therapies can induce life-threatening cardiovascular side effects such as arrhythmias, muscle cell death, or vascular dysfunction. New technologies have enabled cardiotoxic compounds to be identified earlier in drug development. Human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs) and vascular endothelial cells (ECs) can screen for drug-induced alterations in cardiovascular cell function and survival. However, most existing hiPSC models for cardiovascular drug toxicity utilize two-dimensional, immature cells grown in static culture. Improved <i>in vitro</i> models to mechanistically interrogate cardiotoxicity would utilize more adult-like, mature hiP"],"journal":["Lab on a chip"],"pubmed_title":["Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells."],"pmcid":["PMC12015978"],"funding_grant_id":["UG3 TR003148","Allen Distinguished Investigator Award #12879","5UG3NS105703","1UG3TR003148","Career Development Award 856987","856987","UG3 NS105703","T32 HL116273"],"pubmed_authors":["Dezem F","Moser VA","Garcia VJ","Barrett RJ","Svendsen CN","Jenkins A","West D","El-Ghazawi K","Pohlman S","Sances S","Arzt M","Sharma A","Yucer N","Patel S","Mozneb M","Plummer J","Laperle AH","Ho R","Ondatje B","Woodbury A","Workman MJ"],"additional_accession":[]},"is_claimable":false,"name":"Multi-lineage heart-chip models drug cardiotoxicity and enhances maturation of human stem cell-derived cardiovascular cells.","description":"Cardiovascular toxicity causes adverse drug reactions and may lead to drug removal from the pharmaceutical market. Cancer therapies can induce life-threatening cardiovascular side effects such as arrhythmias, muscle cell death, or vascular dysfunction. New technologies have enabled cardiotoxic compounds to be identified earlier in drug development. Human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (CMs) and vascular endothelial cells (ECs) can screen for drug-induced alterations in cardiovascular cell function and survival. However, most existing hiPSC models for cardiovascular drug toxicity utilize two-dimensional, immature cells grown in static culture. Improved <i>in vitro</i> models to mechanistically interrogate cardiotoxicity would utilize more adult-like, mature hiP","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2026-06-01T13:05:38.366Z","creation":"2026-04-08T12:41:49.788Z"},"accession":"S-EPMC12015978","cross_references":{"pubmed":["38252454"],"doi":["10.1039/d3lc00745f"]}}